Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
51 results about "Psychotropic medication" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
List of medications which are used to treat psychiatric conditions that are on the market in the United States (this list is incomplete; the title of the entry is "List of Psychotropic Medications" and what follows is a list of psychiatric drugs – not all psychotropic agents are used to treat psychiatric conditions.)
Neural network drug dosage estimation
InactiveUS6658396B1Improve accuracyGood precisionDrug and medicationsBiological neural network modelsNerve networkPatient characteristics
Neural networks are constructed (programmed), trained on historical data, and used to predict any of (1) optimal patient dosage of a single drug, (2) optimal patient dosage of one drug in respect of the patient's concurrent usage of another drug, (3a) optimal patient drug dosage in respect of diverse patient characteristics, (3b) sensitivity of recommended patient drug dosage to the patient characteristics, (4a) expected outcome versus patient drug dosage, (4b) sensitivity of the expected outcome to variant drug dosage(s), (5) expected outcome(s) from drug dosage(s) other than the projected optimal dosage. Both human and economic costs of both optimal and sub-optimal drug therapies may be extrapolated from the exercise of various optimized and trained neural networks. Heretofore little recognized sensitivities-such as, for example, patient race in the administration of psychotropic drugs-are made manifest. Individual prescribing physicians employing deviant patterns of drug therapy may be recognized. Although not intended to prescribe drugs, nor even to set prescription drug dosage, the neural networks are very sophisticated and authoritative "helps" to physicians, and to physician reviewers, in answering "what if" questions.
Owner:PREDICTION SCI
Method of relieving analgesia and reducing inflamation using a cannabinoid delivery topical liniment
InactiveUS6949582B1Good effectSafe and effectiveBiocideHydroxy compound active ingredientsSide effectCannabinoid receptor
A method of relieving analgesia and reducing inflammation using a cannabinoid delivery topical liniment composition containing from about 97.5% to about 99.5% by weight a 70% monohydric alcohol solution, and from about 0.5% to about 2.5% by weight of a synergistic cannabinoid mixture extracted from the female plant Cannabis sativa L, including in combination: 9-Tetrahydrocannabinol (delta-9-THC), 9-THC Propyl Analogue (THC-V), Cannabidiol (CBD), Cannabidiol Propyl Analogue (CBD-V), Cannabinol (CBN), Cannabichromene (CBC), Cannabichromene Propyl Analogue (CBC-V), Cannabigerol (CBG), terpenoids, and flavonoids. The liniment is applied topically, preferably by spraying, and the constituents of the mixture are absorbed through the skin and interact with cannabinoid receptors in the body and tissues of a human patient to produce therapeutic analgesic and anti-inflammatory effects without undesirable psychotropic side effects.
Owner:WALLACE WALTER H
Conjugated psychotropic drugs and uses thereof
Owner:BAR ILAN UNIV +1
Transdermal absorption promoter, and external skin formulation thereof
InactiveUS20130084257A1Small smellImprove securityCosmetic preparationsBiocideIrritationMethyl group
The present invention provides a substance which promotes the transdermal absorption of a pharmacologically active component while little irritating the skin. The present invention relates to a transdermal absorption promoter which comprises, as the active component, at least one member selected from among isopulegol, 2-(menthoxy)ethanol and 2-methyl-3-(menthoxy)propane-1,2-diol; and an external skin formulation which comprises a pharmacologically active component such as a psychotropic component, an anti-inflammatory component, an analgesic component, an antipyretic component, a whitening component or a hair growth-promoting component, together with the aforesaid transdermal absorption promoter.
Owner:TAKASAGO INTERNATIONAL CORPORATION
Method to Quantitatively Measure Effect of Psychotropic Drugs on Sensory Discrimination
InactiveUS20090220425A1Modulate sensory discriminationImprove representationElectroencephalographySurgeryPsychotropic medicationMedicine
A method for evaluating an effect of a psychotropic compound or a treatment on a neuronal activity of an animal including determining a change in the amount of information generated by neurons in response to at least one repeatedly applied stimulus, wherein the change is caused by administering the psychotropic compound or a treatment. Also provided is a method of screening psychotropic compounds for effectiveness on an animal which involves using a change in sensory discrimination in a population of neurons of the animal, wherein the sensory discrimination is obtained in response to one or more stimuli repeatedly applied to the animal and wherein a change in the sensory discrimination occurs due to administering said psychotropic compounds to the animal.
Owner:DREXEL UNIV
Conjugated psychotropic drugs and uses thereof
InactiveUS20070099977A1Minimize side effectsStrong therapeutic activityBiocideNervous disorderOrganic acidDisease
Owner:BAR ILAN UNIV +1
Software method of determining and treating psychiatric disorders
A software method of determining and treating psychiatric disorders by prompting a user is disclosed. The method includes the steps of defining the decline; assessing potential contributing factors leading to the decline; connecting the potential contributing factors to the decline; diagnosing the decline; addressing the decline and identifying potential contributing factors, and developing a care plan; ensuring adequate management of medical and medication factors; and addressing psychotropic management.
Owner:EISENSTEIN STEVEN
Diphenyl cyclopentyl amides as cannabinoid-1 receptor inverse agonists
Novel compounds of structural formula (I) are antagonists and / or inverse agonists of the Cannabinoid-1 (CB1) receptor and are useful in the treatment, prevention and suppression of diseases mediated by the CB1 receptor. The compounds of the present invention are useful as psychotropic drugs in the treatment of psychosis, memory deficits, cognitive disorders, migraine, neuropathy, neuro-inflammatory disorders including multiple sclerosis and Guillain-Barre syndrome and the inflammatory sequelae of viral encephalitis, cerebral vascular accidents, and head trauma, anxiety disorders, stress, epilepsy, Parkinsons disease, movement disorders, and schizophrenia. The compounds are also useful for the treatment of substance abuse disorders, the treatment of obesity or eating disorders, as well as, the treatment of asthma, constipation, chronic intestinal pseudo-obstruction, and cirrhosis of the liver.
Owner:MERCK SHARP & DOHME CORP
Conjugates comprising a gaba- or glycine compound, pharmaceutical compositions and combinations thereof and their use in treating CNS disorders
InactiveUS20090304584A1Reduce adverse side effectsStrong therapeutic activityBiocideNervous disorderGlycineDisease
Conjugates of a gamma-aminobutyric acid (GABA) compound or a glycine compound and an analgesic drug are disclosed. Further disclosed are pharmaceutical compositions containing these conjugates and uses thereof in the treatment of CNS-associated diseases or disorders, optionally in combination with a psychotropic drug.
Owner:BAR ILAN UNIV +2
Physiogenomic method for predicting diabetes and metabolic syndromes induced by psychotropic drugs
InactiveUS20090075254A1Microbiological testing/measurementFermentationSide effectPsychotropic medication
The invention is generally directed to a physiogenomic method for predicting diabetes and metabolic syndromes induced by psychotropic drugs. In one embodiment, the invention relates to the use of genetic variants of marker genes to predict the likelihood that an individual will experience undesirable metabolic side effects as a result of the use of a drug including, but not limited to, psychotropic drugs. The invention also relates to methods predicting the likelihood of diabetes and metabolic syndromes induced by the use of drugs with undesirable metabolic side effects.
Owner:GENOMAS
Psychotropic agents having glutamate NMDA activity
Owner:RAMOT AT TEL AVIV UNIV LTD
Conjugates Comprising a gaba-or glycine compound, pharmaceutical compositions and combinations thereof as well as their use in treating cns disorders
InactiveUS20100144869A1Strong therapeutic activityAccelerated onset of their protective effectBiocideNervous disorderDiseaseOrganic acid
Owner:RAMOT AT TEL AVIV UNIV LTD +1
Use of metformin to counteract weight gain associated with psychotropic medications
InactiveUS20060246131A1Minimized weight gainBiocideMetabolism disorderSide effectPsychotropic medication
A method for minimizing the weight gain side effect associated with ABILIFY® (aripiprazole) or GEODON® (ziprasidone) treatment is disclosed. In this method, metformin, a biguanide compound, is concurrently administered to a patient taking the ABILIFY® (aripiprazole) or GEODON® (ziprasidone) therapy. A pharmaceutical composition containing the combination of ABILIFY® (aripiprazole) or GEODON® (ziprasidone), together with metformin is also disclosed.
Owner:COTTLINGHAM ELIZABETH M
Covalent conjugates of biologically-active compounds with amino acids and amino acid derivatives for targeting to physiologically-protected sites
InactiveUS7045543B2Efficient ConcentrationMore specificityAntibacterial agentsBiocideAntifungalWhole body
This invention herein describes a method of facilitating the entry of drugs into cells and tissues at physiologically protected sites at pharmacokinetically useful levels and also a method of targeting drugs to physiologically protected sites in vivo. Also provided are drug conjugates with an amino acid or derivative thereof for facilitating such targeted drug delivery. The conjugates and methods of this invention provide an advance over other drug targeting methods known in the prior art, because the invention provides drug concentrations in such physiologically protected sites that can reach therapeutically-effective levels after administration of systemic levels much lower than are currently administered to achieve a therapeutic dose. This technology is appropriate for use with psychotropic, neurotropic, neurological, antibiotic, antibacterial, antimycotic, antiviral, antiproliferative or antineoplastic drugs, agents and conjugates, for rapid and efficient introduction of such agents across, e.g., the blood-brain barrier. Further, the invention provides means for retention and prolonged enzymatic release of such drugs, agents and conjugates comprising the conjugates of the invention, in the brain and central nervous system and other physiologically-protected sites.
Owner:ENZREL
Method and kit for detecting five psychotropic drugs and main metabolites thereof in blood
The invention belongs to the field of drug detection, and particularly relates to a method and a kit for detecting five psychotropic drugs and main metabolites thereof in blood. The five psychotropicdrugs and the main metabolites thereof comprise: olanzapine and demethyl olanzapine, risperidone and 9-hydroxy risperidone, aripiprazole and dehydrogenated aripiprazole, Escitalopram and demethyl citalopram, sertraline and N-demethyl sertraline. Accoridng to the method provided by the invention, a pair of quantitative ion pairs is respectively selected for each detection substance, a relative retention time thereof is used as a qualitative basis, and a standard curve is made by using a standard product for quantification; furthermore, the accuracy and effectiveness of the method are evaluatedfrom quality control of three low, middle and high levels, thereby avoiding distortion of the detection result; and meanwhile, an internal standard working solution is applied to correction, so that matrix effects can be avoided, and accurate quantification is realized. The method provided by the invention has the advantages of simple and rapid operation, high flux and low cost, and can be appliedto the therapeutic drug monitoring of the psychotropic drugs in the clinical work of the psychiatry department.
Owner:BEIJING HUILONGGUAN HOSPITAL +1
The topical composition with active compounds from cannabis sativa and calendula officinalis for reduction of skin lesions
ActiveUS20190111093A1Deep hydrationReduces skin poreCosmetic preparationsOrganic active ingredientsCalendula officinalis extractUltraviolet
Disclosed is a topical composition including essential combination of synergistically acting phyto-active materials, non-psychotropic phytocannabinoids from the plant of Cannabis sativa: Cannabidiol, Cannabidiolic acid, Cannabivarin Cannabigerol in combination with extract of Calendula flower and the formulation of the base to ensure the features of anti-inflammation, anti-oxidation, emollient, and bactericidal components. The topical composition is an emollient dedicated for reduction of skin lesions caused by atopic dermatitis, urticaria, radiotherapy and UV induced skin damage and acne. In addition the topical composition could reduce secretion of fats, facilitate deep skin hydration, reduce pores and exert soothing effect.
Owner:UAB SATIMED
Sustained release injection preparation and preparation method and application thereof
ActiveCN102525915AImprove physical stabilityGood chemical stabilityOrganic active ingredientsNervous disorderPsychotropic medicationDosage form
The invention relates to a sustained release injection preparation and a preparation method and application of the preparation. Specifically, the invention relates to a sustained release injection preparation, which comprises a psychotropic medication and a nonaqueous carrier and can be released in a sustained manner within at least one week. The sustained release injection preparation of the invention has the advantages of better sustained release effect, longer effect, better stability, simple dosage form, no need of lyophilization, eaier preparation process, lower cost, and more convenience for use.
Owner:JIANGSU HANSOH PHARMA CO LTD
Convalent conjugates of biologically-active compounds with amino acids and amino acid derivatives for targeting to physiologically-protected sites
InactiveUS20070129312A1Efficient ConcentrationMore specificityAntibacterial agentsBiocideWhole bodyDrug target
This invention herein describes a method of facilitating the entry of drugs into cells and tissues at physiologically protected sites at pharmacokinetically useful levels and also a method of targeting drugs to physiologically protected sites in vivo. Also provided are drug conjugates with an amino acid or derivative thereof for facilitating such targeted drug delivery. The conjugates and methods of this invention provide an advance over other drug targeting methods known in the prior art, because the invention provides drug concentrations in such physiologically protected sites that can reach therapeutically-effective levels after administration of systemic levels much lower than are currently administered to achieve a therapeutic dose. This technology is appropriate for use with psychotropic, neurotropic, neurological, antibiotic, antibacterial, antimycotic, antiviral, antiproliferative or antineoplastic drugs, agents and conjugates, for rapid and efficient introduction of such agents across, e.g., the blood-brain barrier. Further, the invention provides means for retention and prolonged enzymatic release of such drugs, agents and conjugates comprising the conjugates of the invention, in the brain and central nervous system and other physiologically-protected sites.
Owner:YATVIN MILTON B +1
Spirocyclic amides as cannabinoid receptor modulators
Novel compounds of structural formula (I) are antagonists and / or inverse agonists of the Cannabinoid-1 (CB1) receptor and are useful in the treatment, prevention and suppression of diseases mediated by the CB1 receptor. The compounds of the present invention are useful as psychotropic drugs in the treatment of psychosis, memory deficits, cognitive disorders, migraine, neuropathy, neuro-inflammatory disorders including multiple sclerosis and Guillain-Barre syndrome and the inflammatory sequelae of viral encephalitis, cerebral vascular accidents, and head trauma, anxiety disorders, stress, epilepsy, Parkinsons disease, movement disorders, and schizophrenia. The compounds are also useful for the treatment of substance abuse disorders, the treatment of obesity or eating disorders, as well as, the treatment of asthma, constipation, chronic intestinal pseudo-obstruction, and cirrhosis of the liver.
Owner:MERCK SHARP & DOHME CORP
Benzylisoquinoline derivative- or bisbenzylisoquinoline derivative-containing psychotropic agent, analgesic and/or antiphlogistic, and health food
InactiveUS20070027181A1Preventing and alleviating painInflammation can be prevented and alleviatedBiocideNervous disorderPsychotropic medicationAdditive ingredient
A psychotropic agent, analgesic and / antiinflammatory agent, or health food which is safe even when taken for an extended period of term, comprising as an effective ingredient a benzylisoquinoline derivative represented by general formula (I): or a bisbenzylisoquinoline derivative represented by general formula (II): or a pharmaceutically acceptable salt thereof.
Owner:EDUCATION CENT OF TRADITIONAL CHINESE MEDICINE +1
Substituted imidazoles as cannabinoid receptor modulators
Owner:MERCK SHARP & DOHME CORP
Substituted phenylpiperidines with serotoninergic activity and enhanced therapeutic properties
InactiveCN101360742AOrganic active ingredientsNervous disorderCompulsive disordersDiabetic retinopathy
Chemical syntheses and medical uses of novel inhibitors of the uptake of monoamine neurotransmitters and pharmaceutically acceptable salts and prodrugs thereof, for the treatment and / or management of psychotropic disorders, anxiety disorder, generalized anxiety disorder, depression, post-traumatic stress disorder, obsessive- compulsive disorder, panic disorder, hot flashes, senile dementia, migraine, hepatopulmonary syndrome, chronic pain, nociceptive pain, neuropathic pain, painful diabetic retinopathy, bipolar depression, obstructive sleep apnea, psychiatric disorders, premenstrual dysphoric disorder, social phobia, social anxiety disorder, urinary incontinence, anorexia, bulimia nervosa, obesity, ischemia, head injury, calcium overload in brain cells, drug dependence, and / or premature ejaculation are described.
Owner:AUSPEX PHARMA INC
Multiparticulate L-Carnitine And Nootropic Compositions And Related Methods
InactiveUS20170231940A1Inhibition releaseEfficient releaseOrganic active ingredientsGranular deliveryParticulatesPsychotropic medication
A composition includes a therapeutically effective pharmaceutical dosage form including a plurality of individual particulates. The individual particulates respectively have: a core including an active ingredient combination of an L-carnitine and a nootropic substance and a release controlling polymer over the core that substantially prevents release of the active ingredients in stomach acid and permits release of the active ingredients in an intestinal pH environment. The composition may be used to treat conditions associated with a reduction of the amount of L-carnitine in the body and / or cognitive impairment.
Owner:SOC DES PROD NESTLE SA
Neuroprotective properties of dextrorotatory morphinans
Owner:KNU IND COOPERATION FOUND
Method to Predict Response to Neuropsychiatric Drugs Using Variation in the Serotonin 7 Receptor (HTR7) Gene
Provided herein are, inter alia, methods whereby response to psychotropic drugs can be predicted, methods of treating neuropsychiatric disorders, and methods of detecting a single nucleotide polymorphism (SNP) relating to treating neuropsychiatric disorders.
Owner:RGT UNIV OF CALIFORNIA
The oleo gel composition and delivery system with active compounds from cannabis sativa and mentha arvensis for reduction of inflammation and pain in deep tissues
ActiveUS20190167749A1Reduce impactOrganic active ingredientsNervous disorderArthritisSilicon dioxide
Disclosed is an oleo gel composition including essential combination of synergistically acting phyto-active materials, non-psychotropic phytocannabinoids from the plant of Cannabis sativa: Cannabidiol, Cannabidiolic acid, Cannabivarin and Cannabigerol in combination with extract of Olive europaea Fruit Oil, Mentha arvensis leaf oil, and Silica colloidal anhydrous ensuring the delivery of cannabinoids to the deep tissues in order to reduce pain and inflammation of skeletal muscles and joints caused by trauma or / and induced by arthritis / osteoarthritis.
Owner:UAB SATIMED
Psychotropic drug screening device based on long-term photoconductive stimulation of neurons
InactiveUS20060292549A1Simulating activityRapid and cost-effective testingBioreactor/fermenter combinationsBiological substance pretreatmentsSterile environmentNeuron network
The invention pertains generally to the field of psychotropic drug discovery and neuroscience. More specifically, the invention refers to a device that allows the long-term stimulation of cultured neurons grown on a silicon die, thereby replacing the use of intact animal models. The device consists of a controlled sterile environment in which the neuronal cultures can grow, and into which specific candidate compounds (e.g., psychotropic drugs) are added. During the period of growth, which can be extended for months, specifically tailored patterned activity can be applied to the neuronal network, simulating the activity normally found in a brain. The neuronal networks are grown on a silicon surface which is targeted by a light source, which functions to alter the connectivity of the surface below a specific group of cells. Cells on this targeted region are caused to fire on a brief electrical pulse. Upon completion of the growth period the silicon die can be removed and subject to electrophysiological and biochemical analysis.
Owner:NEUROSILICON 1145990 ALBERTA
Psychotropic agents and uses thereof
Novel amisulpride derivatives and pharmaceutical compositions thereof are disclosed. The amisulpride derivative disclosed herein or a pharmaceutical composition thereof may have better membrane permeability compared to amisulpride. The amisulpride derivative disclosed herein or a pharmaceutical composition thereof may be used for antagonizing dopamine and / or serotonin (e.g., 5-HT2a) and / or α2 receptor in a subject, either individually or in combination with other CNS active agents. The amisulpride derivative disclosed herein or a pharmaceutical composition thereof may be used for treating one or more conditions responsive to modulation of dopamine and / or serotonin (e.g., 5-HT2a) and / or α2 receptor in a subject, either individually or in combination with other CNS active agents. The amisulpride derivative disclosed herein or a pharmaceutical composition thereof may be used for treating one or more disorders associated with an abnormality in levels of dopamine and / or serotonin in the brain, either individually or in combination with other CNS active agents.
Owner:LB PHARMA INC
Methods for predicting psychotropic drugs which elicit weight gain
ActiveUS8148095B2Compound screeningNervous disorderManagement of schizophreniaAtypical antipsychotic
The atypical antipsychotic drugs (AAPDs) have markedly enhanced the treatment of schizophrenias but their use has been hindered by the major weight gain elicited by some AAPDs. We found that orexigenic AAPDs potently and selectively activate hypothalamic AMP kinase (AMPK), an action abolished in mice with deletion of histamine H1 receptors. These findings afford a means of developing better therapeutic agents and provide insight into the hypothalamic regulation of food intake.
Owner:THE JOHN HOPKINS UNIV SCHOOL OF MEDICINE +1
Psychotropic compounds, compositions and methods of use
The present invention provides a method for treating or preventing a disease or disorder treatable by the inhibition of serotonin reuptake in a patient, and / or norepinephrine reuptake and / or dopamine reuptake in a patient, the method comprising administering to the patient a neurotransmitter reuptake inhibiting-effective amount of at least one compound of the formula A-L-B (I) or a pharmaceutically acceptable salt, ester or prodrug thereof, wherein A is a psychotropic derivative; L is a linking group comprising two carbon atoms; and B is an alkyl, alkenyl, alkynyl or aralkyl comprising at least one substituent of the formula Q, wherein: the alkyl, alkenyl, alkynyl or aralkyl is optionally substituted with one or more halogean halogens, hydroxyl, cyano, nitro, amino or thiol; and Q is OR6, OC(O)R6, C(O)R6, C(S)R6, CO2R6, C(O)SR6, C(O)NR6R7, C(S)NR6R7, NR6R7, NR6C(O)R7, NR6C(S)R7, NR6C(O)NR7R8, NR6C(S)NR7R8, NR6SO2R7, NR6SO2NR7R8, SR6, SC(O)R6, SC(O)NR6R7, S(O)R6, SO2R6, SO2NR6R7, or NR6SO2NR7R8.
Owner:RAMOT AT TEL AVIV UNIV LTD
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com